News

New Patent for Caretaker Medical

Caretaker Medical has received issuance of a new Patent by the United States Patent and Trademark Office (USPTO) for self-calibrating systems for blood pressure wave form analysis and diagnostics, U.S. Patent No. 11,207,034, further strengthening the Company’s intellectual property position and coverage for the Company’s medical-grade continuous digital blood pressure and vital sign monitoring system.

“We are pleased to announce this new patent that is especially important for patient care as it enables ultra-fast, 30-second auto-calibration of arterial blood pressure, which is an essential measurement for cardiovascular health. This provides a big advantage over existing continuous blood pressure monitoring systems that require additional arm cuff calibration measurements, which add costly delays to set up time and patient care,” commented Jeff Pompeo, President and Chief Executive Officer of Caretaker Medical.

Caretaker Medical, a pioneer in wireless “beat-by-beat” hemodynamic monitoring technology, now has six issued patents in the U.S., Europe, and Asia, adding to the long-term value of our medical-grade VitalStream™ continuous patient monitoring system.

Learn more about Caretaker Medical here.

Recent News

05/08/2026

RIVANNA Receives FDA 510(k) Clearance for Accuro XV Musculoskeletal Ultrasound Imaging System

RIVANNA®, developer of AI-enabled clinical decision-support solutions, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the Accuro® XV Diagnostic Ultrasound System. The clearance marks a pivotal regulatory milestone for RIVANNA, authorizing commercial use of the Accuro XV for musculoskeletal imaging by qualified and trained healthcare professionals in hospital

05/06/2026

RoVa Labs Opens as Transformational Investment in Roanoke Region’s Innovation Economy

Leaders from Carilion Clinic, the City of Roanoke, Roanoke Blacksburg Innovation Alliance (RBIA), and Virginia Western Community College cut the ribbon on years of hard work with the opening of RoVa Labs, a 40,000-square-foot biotech incubator designed to accelerate commercialization, strengthen the Roanoke Innovation Corridor, and position the region as an emerging destination for life

05/04/2026

ISOThrive Reports Highly Statistically Significant Phase 2 Data for MHS-1031 in NERD PPI-Partial Responder Patients at DDW 2026

ISOThrive Inc. announced positive Phase 2 results for MHS-1031 treating NERD patients with incomplete response to proton pump inhibitors (PPIs), demonstrating statistically significant and clinically meaningful reductions in heartburn incidence, severity, and regurgitation. The company’s Chief Medical Officer is presenting these results at Digestive Disease Week (DDW) 2026 this week. NERD represents approximately 70% of